Real-World Evidence of Successful Product Commercialization

In this AJMC Industry Outlook webinar "The Role of Real-World Evidence in Successful Product Commercialization," we discuss a framework to identify and validate the need for external customer-facing evidence generation and review how the framework can be applied. By the end of this discussion, you will have a deeper understanding of how to frame and justify investment in health economics and outcomes research, and real-world evidence generation.

Related Videos

Related Content

Advertisement

April 30th 2025

Keep Patients at the Center of Clinical Research

Maggie L. Shaw

Experts emphasize the need for enhanced clinical trial infrastructure in community oncology to ensure equitable access to innovative therapies for all patients.

April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD

On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.

April 30th 2025

Expanding Broader Patient Access to CGTs

Pearl Steinzor

Key trends and challenges are shaping the next era of advanced therapies, from FDA momentum to broader patient access.

April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

April 30th 2025

FDA Approves Nipocalimab for Generalized Myasthenia Gravis

Christina Mattina

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older with generalized myasthenia gravis based on data from the ongoing Vivacity-MG3 study.

April 30th 2025

Assessing the Complex Interplay Between Metabolic Dysfunction and Rheumatoid Arthritis

Jared Kaltwasser

Many studies have examined how rheumatoid arthritis therapy affects the risk of metabolic comorbidities.

Related Content

Advertisement

April 30th 2025

Keep Patients at the Center of Clinical Research

Maggie L. Shaw

Experts emphasize the need for enhanced clinical trial infrastructure in community oncology to ensure equitable access to innovative therapies for all patients.

April 22nd 2025

New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix

Brooke McCormick Brady Post, PhD

On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.

April 30th 2025

Expanding Broader Patient Access to CGTs

Pearl Steinzor

Key trends and challenges are shaping the next era of advanced therapies, from FDA momentum to broader patient access.

April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD

Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.

April 30th 2025

FDA Approves Nipocalimab for Generalized Myasthenia Gravis

Christina Mattina

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older with generalized myasthenia gravis based on data from the ongoing Vivacity-MG3 study.

April 30th 2025

Assessing the Complex Interplay Between Metabolic Dysfunction and Rheumatoid Arthritis

Jared Kaltwasser

Many studies have examined how rheumatoid arthritis therapy affects the risk of metabolic comorbidities.